The role of tenofovir in preventing and treating hepatitis B virus (HBV) reactivation in immunosuppressed patients. A real life experience from a tertiary center

European Journal of Internal Medicine

Volumn 25, Issue 8, 2014, Pages 768-771

  Koskinas, J S ^a   Deutsch, M ^a   Adamidi, S ^a   Skondra, M ^a   Tampaki, M ^a   Alexopoulou, A ^a   Manolakopoulos, S ^a   Pectasides, D ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

HBV reactivation; Immunosuppression; Tenofovir

Indexed keywords

CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETANERCEPT; FLUOROURACIL; HEPATITIS B SURFACE ANTIGEN; METHYLPREDNISOLONE; PREDNISOLONE; RITUXIMAB; TENOFOVIR; USTEKINUMAB; VINCRISTINE; VIRUS DNA; ADENINE; ANTIVIRUS AGENT; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; PHOSPHONIC ACID DERIVATIVE;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ANTIVIRAL THERAPY; ARTICLE; ASTHMA; BREAST CANCER; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; DECOMPENSATED LIVER CIRRHOSIS; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG USE; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; NONHODGKIN LYMPHOMA; PERSONAL EXPERIENCE; PSORIASIS; RHEUMATOID ARTHRITIS; SEROCONVERSION; TERTIARY CARE CENTER; TREATMENT RESPONSE; VIRUS REACTIVATION; WEGENER GRANULOMATOSIS; ANALOGS AND DERIVATIVES; DRUG EFFECTS; IMMUNOCOMPROMISED PATIENT; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; VERY ELDERLY; VIRUS ACTIVATION;

ADENINE; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIVIRAL AGENTS; FEMALE; HEPATITIS B; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOLOGIC FACTORS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; VIRUS ACTIVATION;

EID: 84908167592     PISSN: 09536205     EISSN: 18790828     Source Type: Journal    
DOI: 10.1016/j.ejim.2014.06.028     Document Type: Article

References (22)

1. EASL clinical practice guidelines: management of chronic hepatitis B J Hepatol 57 2012 167 185
2. D. Lavanchy Hepatitis B virus epidemiology, disease burden, treatment and current and emerging prevention and control measures J Viral Hepat 11 2004 97 107
3. H.L. Chan, and J.J. Sung Hepatocellular carcinoma and hepatitis B virus Semin Liver Dis 26 2006 153 161
4. F.J. van Hemert, H.L. Zaaijer, B. Berkhout, and V.V. Lukashov Occult hepatitis B infection: an evolutionary scenario Virol J 5 2008 146
5. A. Lok, and P. Bonis Hepatitis B virus reactivation associated with immunosuppression Up to date.com. 2013
6. J.H. Hoofnagle Reactivation of hepatitis B Hepatology 49 No5, Suppl. 2009 S156 S165
7. W. Yeo, T.C. Chan, N.W. Leung, W.Y. Lam, F.K. Mo, and M.T. Chu Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab J Clin Oncol 27 2009 605 611
8. R. Liang How I, treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation Blood 113 2009 3147 3153
9. D. Vassilopoulos, and L.H. Calabrese Risks of immunosuppressive therapies including biologic agents in patients with rheumatic diseases and co-existing chronic viral infections Curr Opin Rheumatol 19 2007 619 625
10. L.H. Katz, A. Fraser, A. Gafter-Gvili, L. Leibovici, and R. Tur-Kaspa Lamivudine prevents reactivation of hepatitis b and reduces mortality in immunosuppressed patients: systematic review and meta-analysis J Viral Hepat 15 2008 89 102
11. J. Heathcote Treatment of HBe antigen-positive chronic hepatitis B Semin Liver Dis 23 2003 69 80
12. S.J. Hadziyannis, G.V. Papatheodoridis, and D. Vassilopoulos Treatment of HBeAg-negative chronic hepatitis B Semin Liver Dis 23 2003 81 88
13. C.L. Lai, J. Dienstag, E. Schiff, N.W. Leung, M. Atkins, and C. Hunt Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B Clin Infect Dis 36 2003 687 696
14. C. Hsu, C.A. Hsiung, I.J. Su, W.S. Hwang, M.C. Wang, and S.F. Lin A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial Hepatology 47 2008 844 853
15. T.M. Chan, G.X. Fang, C.S. Tang, I.K. Cheng, K.N. Lai, and S.K. Ho Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients Hepatology 36 2002 1246 1252
16. D. Vassilopoulos, A. Apostolopoulou, E. Hadziyannis, G.V. Papatheodoridis, S. Manolakopoulos, and J. Koskinas Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection Ann Rheum Dis 69 7 Jul 2010 1352 1355 [Epub 2010 May 14]
17. V. Svicher, C. Alteri, C. Gori, R. Salpini, F. Marcuccilli, and A. Bertoli Lamivudine-resistance mutations can be selected even at very low levels of hepatitis B viraemia Dig Liver Dis. 42 12 2010 902 907
18. M. Deutsch, N. Papadopoulos, S. Manolakopoulos, E. Hatziyanni, and D. Vassilopoulos Fatal hepatitis B virus reactivation due to a lamivudine mutant despite undetectable initial viral load Eur J Gastroenterol Hepatol 23 2011 109
19. S. Brost, P. Schnitzler, W. Stremmel, and C. Eisenbach Entecavir as treatment for reactivation of hepatitis B in immunosupressed patients World J Gastroenterol 16 2010 5447 5451
20. L. Milazzo, M. Corbellino, A. Foschi, V. Micheli, A. Dodero, and A. Mazzocchi Late onset of hepatitis B virus reactivation following hematopoietic stem cell transplantation: successful treatment with combined entecavir plus tenofovir therapy Transpl Infect Dis 14 1 Feb 2012 95 98
21. A. Rago, M. Lichtner, S. Mecarocci, R. Marocco, N. Cenfra, and V. Belvisi Antiviral treatment including entecavir plus tenofovir disoproxil fumarate for HBV reactivation following a rituximab-based regimen Antivir Ther 15 6 2010 929 932
22. H. Garg, S.K. Sarin, M. Kumar, V. Garg, B.C. Sharma, and A. Kumar Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute on chronic liver failure Hepatology 53 2011 774 780